Crosscheck

Your medical. Crosschecked.

Check another medication

Tamoxifen

Other names: Nolvadex

The FAA's guidance for tamoxifen depends on what it is taken for. Each use is below, with its own FAA source and date.

Taken for low testosterone (hypogonadism)

FAA guidance

Acceptable with conditions.

Examiner

CACI: the examiner can issue when the condition's worksheet criteria are met. Applicants for first- or second-class must provide the worksheet's information annually; applicants for third-class with each required exam

Source: FAA, Low Testosterone (Low T) Hypogonadism. FAA date 29 April 2026. Checked by Crosscheck 14 October 2026

For low testosterone (hypogonadism), the FAA's table lists tamoxifen among the treatments of its row B, which goes to the CACI hypogonadism worksheet: it requires a complete blood count (CBC) and a current, detailed clinical progress note from the treating physician or a completed Low T status summary, and the examiner issues if the pilot meets all the CACI worksheet criteria and is otherwise qualified.

Track your medications
Show the FAA's words: tamoxifenThe official FAA wording: one passage, each with its document and dateOpen
FAA, Low Testosterone (Low T) Hypogonadism · FAA date 29 April 2026
LOW TESTOSTERONE (LOW T) HYPOGONADISM
B. Treated with one or more of the following:
Anastrozole
Clomiphene citrate
Human Chorionic Gonadotropin (HCG)
Testosterone (Oral or Injectable)
Testopel
Tamoxifen
See the CACI - Hypogonadism Worksheet.
This requires a complete blood count (CBC) lab AND a current, detailed Clinical Progress Note from the treating physician OR a completed Low Testosterone (Low T) Hypogonadism Status Summary
If the pilot meets all CACI worksheet criteria and is otherwise qualified:
ISSUE
Sources and dates: tamoxifenOne FAA document, with the FAA's date and when Crosscheck checked itOpen

Taken for breast cancer

FAA guidance

Acceptable with conditions.

Examiner

CACI: the examiner can issue when the condition's worksheet criteria are met. Applicants for first- or second-class must provide the worksheet's information annually; applicants for third-class with each required exam

Source: FAA, CACI – Breast Cancer Worksheet. FAA date 27 April 2022. Checked by Crosscheck 14 October 2026

For breast cancer, the FAA's CACI – Breast Cancer Worksheet lists tamoxifen (Nolvadex) among its approved medications, when it is being well tolerated with no side effects.

More detail: tamoxifenThe rest of Crosscheck's reading, in plain wordsOpen

The worksheet applies when the pathology showed carcinoma in situ (Tis), stage 0, ductal or lobular carcinoma in situ, or Paget disease of the breast, with all its other criteria, and the examiner must note in Block 60 one of its statements, which include CACI qualified and not CACI qualified.

Show the FAA's words: tamoxifenThe official FAA wording: one passage, each with its document and dateOpen
FAA, CACI – Breast Cancer Worksheet · FAA date 27 April 2022
The pathology showed:
Carcinoma in Situ (Tis), Stage 0;
Ductal Carcinoma in Situ (DCIS);
Lobular Carcinoma in Situ (LCIS);
Paget disease of the breast (Tis)
Current medication(s):
Approved medications include:
tamoxifen (Nolvadex);
Aromatase inhibitors: anastrozole (Arimidex), letrozole (Femara), or exemestane (Aromasin)
An approved medication that is being well tolerated with no side effects
AME MUST NOTE in Block 60 one of the following:
CACI qualified breast cancer (Documents do not need to be submitted to the FAA.)
NOT CACI qualified breast cancer.
Sources and dates: tamoxifenOne FAA document, with the FAA's date and when Crosscheck checked itOpen

Taking it for something else? The entries here do not cover that use. The FAA may address it in the guidance for your condition. Ask your examiner.

See also

Medication guidance alone does not determine whether a pilot is medically qualified to fly. The underlying condition, dosage, side effects, medication combinations, and certification history may affect FAA eligibility.

For informational purposes only. Not legal or medical advice.